

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 2663
Steven M. RUBEN	Art Unit: 1644
Appl. No.: 10/662,429	Examiner: HUYNH, PHUONG N.
Filed: September 16, 2003	Atty. Docket: 1488.1890003/EJH/SAC
For: Apoptosis Inducing Molecule I	

**Declaration of Steven M. Ruben
Ruben Exhibit #157**

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100
101
102
103
104
105
106
107
108
109
110
111
112
113
114
115
116
117
118
119
120
121
122
123
124
125
126
127
128
129
130
131
132
133
134
135
136
137
138
139
140
141
142
143
144
145
146
147
148
149
150
151
152
153
154
155
156
157
158
159
160
161
162
163
164
165
166
167
168
169
170
171
172
173
174
175
176
177
178
179
180
181
182
183
184
185
186
187
188
189
190
191
192
193
194
195
196
197
198
199
200
201
202
203
204
205
206
207
208
209
210
211
212
213
214
215
216
217
218
219
220
221
222
223
224
225
226
227
228
229
230
231
232
233
234
235
236
237
238
239
240
241
242
243
244
245
246
247
248
249
250
251
252
253
254
255
256
257
258
259
259
260
261
262
263
264
265
266
267
268
269
270
271
272
273
274
275
276
277
278
279
280
281
282
283
284
285
286
287
288
289
290
291
292
293
294
295
296
297
298
299
300
301
302
303
304
305
306
307
308
309
310
311
312
313
314
315
316
317
318
319
320
321
322
323
324
325
326
327
328
329
330
331
332
333
334
335
336
337
338
339
339
340
341
342
343
344
345
346
347
348
349
349
350
351
352
353
354
355
356
357
358
359
359
360
361
362
363
364
365
366
367
368
369
369
370
371
372
373
374
375
376
377
378
379
379
380
381
382
383
384
385
386
387
388
389
389
390
391
392
393
394
395
396
397
398
399
399
400
401
402
403
404
405
406
407
408
409
409
410
411
412
413
414
415
416
417
418
419
419
420
421
422
423
424
425
426
427
428
429
429
430
431
432
433
434
435
436
437
438
439
439
440
441
442
443
444
445
446
447
448
449
449
450
451
452
453
454
455
456
457
458
459
459
460
461
462
463
464
465
466
467
468
469
469
470
471
472
473
474
475
476
477
478
479
479
480
481
482
483
484
485
486
487
488
489
489
490
491
492
493
494
495
496
497
498
499
499
500
501
502
503
504
505
506
507
508
509
509
510
511
512
513
514
515
516
517
518
519
519
520
521
522
523
524
525
526
527
528
529
529
530
531
532
533
534
535
536
537
538
539
539
540
541
542
543
544
545
546
547
548
549
549
550
551
552
553
554
555
556
557
558
559
559
560
561
562
563
564
565
566
567
568
569
569
570
571
572
573
574
575
576
577
578
579
579
580
581
582
583
584
585
586
587
588
589
589
590
591
592
593
594
595
596
597
598
599
599
600
601
602
603
604
605
606
607
608
609
609
610
611
612
613
614
615
616
617
618
619
619
620
621
622
623
624
625
626
627
628
629
629
630
631
632
633
634
635
636
637
638
639
639
640
641
642
643
644
645
646
647
648
649
649
650
651
652
653
654
655
656
657
658
659
659
660
661
662
663
664
665
666
667
668
669
669
670
671
672
673
674
675
676
677
678
679
679
680
681
682
683
684
685
686
687
688
689
689
690
691
692
693
694
695
696
697
698
699
699
700
701
702
703
704
705
706
707
708
709
709
710
711
712
713
714
715
716
717
718
719
719
720
721
722
723
724
725
726
727
728
729
729
730
731
732
733
734
735
736
737
738
739
739
740
741
742
743
744
745
746
747
748
749
749
750
751
752
753
754
755
756
757
758
759
759
760
761
762
763
764
765
766
767
768
769
769
770
771
772
773
774
775
776
777
778
779
779
780
781
782
783
784
785
786
787
788
789
789
790
791
792
793
794
795
796
797
798
799
799
800
801
802
803
804
805
806
807
808
809
809
810
811
812
813
814
815
816
817
818
819
819
820
821
822
823
824
825
826
827
828
829
829
830
831
832
833
834
835
836
837
838
839
839
840
841
842
843
844
845
846
847
848
849
849
850
851
852
853
854
855
856
857
858
859
859
860
861
862
863
864
865
866
867
868
869
869
870
871
872
873
874
875
876
877
878
879
879
880
881
882
883
884
885
886
887
888
889
889
890
891
892
893
894
895
896
897
898
899
899
900
901
902
903
904
905
906
907
908
909
909
910
911
912
913
914
915
916
917
918
919
919
920
921
922
923
924
925
926
927
928
929
929
930
931
932
933
934
935
936
937
938
939
939
940
941
942
943
944
945
946
947
948
949
949
950
951
952
953
954
955
956
957
958
959
959
960
961
962
963
964
965
966
967
968
969
969
970
971
972
973
974
975
976
977
978
979
979
980
981
982
983
984
985
986
987
988
989
989
990
991
992
993
994
995
996
997
998
999
1000
1001
1002
1003
1004
1005
1006
1007
1008
1009
1009
1010
1011
1012
1013
1014
1015
1016
1017
1018
1019
1019
1020
1021
1022
1023
1024
1025
1026
1027
1028
1029
1029
1030
1031
1032
1033
1034
1035
1036
1037
1038
1039
1039
1040
1041
1042
1043
1044
1045
1046
1047
1048
1049
1049
1050
1051
1052
1053
1054
1055
1056
1057
1058
1059
1059
1060
1061
1062
1063
1064
1065
1066
1067
1068
1069
1069
1070
1071
1072
1073
1074
1075
1076
1077
1078
1079
1079
1080
1081
1082
1083
1084
1085
1086
1087
1088
1089
1089
1090
1091
1092
1093
1094
1095
1096
1097
1098
1098
1099
1099
1100
1101
1102
1103
1104
1105
1106
1107
1108
1109
1109
1110
1111
1112
1113
1114
1115
1116
1117
1118
1119
1119
1120
1121
1122
1123
1124
1125
1126
1127
1128
1129
1129
1130
1131
1132
1133
1134
1135
1136
1137
1138
1139
1139
1140
1141
1142
1143
1144
1145
1146
1147
1148
1149
1149
1150
1151
1152
1153
1154
1155
1156
1157
1158
1159
1159
1160
1161
1162
1163
1164
1165
1166
1167
1168
1169
1169
1170
1171
1172
1173
1174
1175
1176
1177
1178
1179
1179
1180
1181
1182
1183
1184
1185
1186
1187
1188
1189
1189
1190
1191
1192
1193
1194
1195
1196
1197
1198
1198
1199
1199
1200
1201
1202
1203
1204
1205
1206
1207
1208
1209
1209
1210
1211
1212
1213
1214
1215
1216
1217
1218
1219
1219
1220
1221
1222
1223
1224
1225
1226
1227
1228
1229
1229
1230
1231
1232
1233
1234
1235
1236
1237
1238
1239
1239
1240
1241
1242
1243
1244
1245
1246
1247
1248
1249
1249
1250
1251
1252
1253
1254
1255
1256
1257
1258
1259
1259
1260
1261
1262
1263
1264
1265
1266
1267
1268
1269
1269
1270
1271
1272
1273
1274
1275
1276
1277
1278
1279
1279
1280
1281
1282
1283
1284
1285
1286
1287
1288
1289
1289
1290
1291
1292
1293
1294
1295
1296
1297
1298
1298
1299
1299
1300
1301
1302
1303
1304
1305
1306
1307
1308
1309
1309
1310
1311
1312
1313
1314
1315
1316
1317
1318
1319
1319
1320
1321
1322
1323
1324
1325
1326
1327
1328
1329
1329
1330
1331
1332
1333
1334
1335
1336
1337
1338
1339
1339
1340
1341
1342
1343
1344
1345
1346
1347
1348
1349
1349
1350
1351
1352
1353
1354
1355
1356
1357
1358
1359
1359
1360
1361
1362
1363
1364
1365
1366
1367
1368
1369
1369
1370
1371
1372
1373
1374
1375
1376
1377
1378
1379
1379
1380
1381
1382
1383
1384
1385
1386
1387
1388
1389
1389
1390
1391
1392
1393
1394
1395
1396
1397
1398
1398
1399
1399
1400
1401
1402
1403
1404
1405
1406
1407
1408
1409
1409
1410
1411
1412
1413
1414
1415
1416
1417
1418
1419
1419
1420
1421
1422
1423
1424
1425
1426
1427
1428
1429
1429
1430
1431
1432
1433
1434
1435
1436
1437
1438
1439
1439
1440
1441
1442
1443
1444
1445
1446
1447
1448
1449
1449
1450
1451
1452
1453
1454
1455
1456
1457
1458
1459
1459
1460
1461
1462
1463
1464
1465
1466
1467
1468
1469
1469
1470
1471
1472
1473
1474
1475
1476
1477
1478
1479
1479
1480
1481
1482
1483
1484
1485
1486
1487
1488
1489
1489
1490
1491
1492
1493
1494
1495
1496
1497
1498
1498
1499
1499
1500
1501
1502
1503
1504
1505
1506
1507
1508
1509
1509
1510
1511
1512
1513
1514
1515
1516
1517
1518
1519
1519
1520
1521
1522
1523
1524
1525
1526
1527
1528
1529
1529
1530
1531
1532
1533
1534
1535
1536
1537
1538
1539
1539
1540
1541
1542
1543
1544
1545
1546
1547
1548
1549
1549
1550
1551
1552
1553
1554
1555
1556
1557
1558
1559
1559
1560
1561
1562
1563
1564
1565
1566
1567
1568
1569
1569
1570
1571
1572
1573
1574
1575
1576
1577
1578
1579
1579
1580
1581
1582
1583
1584
1585
1586
1587
1588
1589
1589
1590
1591
1592
1593
1594
1595
1596
1597
1598
1598
1599
1599
1600
1601
1602
1603
1604
1605
1606
1607
1608
1609
1609
1610
1611
1612
1613
1614
1615
1616
1617
1618
1619
1619
1620
1621
1622
1623
1624
1625
1626
1627
1628
1629
1629
1630
1631
1632
1633
1634
1635
1636
1637
1638
1639
1639
1640
1641
1642
1643
1644
1645
1646
1647
1648
1649
1649
1650
1651
1652
1653
1654
1655
1656
1657
1658
1659
1659
1660
1661
1662
1663
1664
1665
1666
1667
1668
1669
1669
1670
1671
1672
1673
1674
1675
1676
1677
1678
1679
1679
1680
1681
1682
1683
1684
1685
1686
1687
1688
1689
1689
1690
1691
1692
1693
1694
1695
1696
1697
1698
1698
1699
1699
1700
1701
1702
1703
1704
1705
1706
1707
1708
1709
1709
1710
1711
1712
1713
1714
1715
1716
1717
1718
1719
1719
1720
1721
1722
1723
1724
1725
1726
1727
1728
1729
1729
1730
1731
1732
1733
1734
1735
1736
1737
1738
1739
1739
1740
1741
1742
1743
1744
1745
1746
1747
1748
1749
1749
1750
1751
1752
1753
1754
1755
1756
1757
1758
1759
1759
1760
1761
1762
1763
1764
1765
1766
1767
1768
1769
1769
1770
1771
1772
1773
1774
1775
1776
1777
1778
1779
1779
1780
1781
1782
1783
1784
1785
1786
1787
1788
1789
1789
1790
1791
1792
1793
1794
1795
1796
1797
1798
1798
1799
1799
1800
1801
1802
1803
1804
1805
1806
1807
1808
1809
1809
1810
1811
1812
1813
1814
1815
1816
1817
1818
1819
1819
1820
1821
1822
1823
1824
1825
1826
1827
1828
1829
1829
1830
1831
1832
1833
1834
1835
1836
1837
1838
1839
1839
1840
1841
1842
1843
1844
1845
1846
1847
1848
1849
1849
1850
1851
1852
1853
1854
1855
1856
1857
1858
1859
1859
1860
1861
1862
1863
1864
1865
1866
1867
1868
1869
1869
1870
1871
1872
1873
1874
1875
1876
18

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of:	Confirmation No.: 2663
Steven M. RUBEN	Art Unit: 1644
Appl. No.: 10/662,429	Examiner: HUYNH, PHUONG N.
Filed: September 16, 2003	Atty. Docket: 1488.1890003/EJH/SAC
For: Apoptosis Inducing Molecule I	

**Declaration of Steven M. Ruben
Ruben Exhibit #157**

Paper No. _____

Filed on Behalf of Party Ruben:

By: Samuel B. Abrams, Esq.
Margaret B. Brivanlou, Esq.
JONES DAY
222 East 41st Street
New York, New York 10017
Tel: (212) 326-3939
Fax: (212) 755-7306

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
(Administrative Patent Judge Sally Gardner Lane)

STEVEN M. RUBEN

Junior Party,
(Application No. 08/816,981),

v.

STEVEN R. WILEY
and RAYMOND G. GOODWIN

Senior Party,
(Patent No. 5,763,223).

Patent Interference No. 105,077

DECLARATION OF STEVEN M. RUBEN

Ruben EXHIBIT 2157
Ruben v. Wiley et al.
Interference 105,077

Paper No. _____

Filed on Behalf of Party Ruben:

By: **Samuel B. Abrams, Esq.**
Margaret B. Brivanlou, Esq.
JONES DAY
222 East 41st Street
New York, New York 10017
Tel: (212) 326-3939
Fax: (212) 755-7306

UNITED STATES PATENT AND TRADEMARK OFFICE

**BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES**
(Administrative Patent Judge Sally Gardner Lane)

STEVEN M. RUBEN

Junior Party,
(Application No. 08/816,981),

v.

STEVEN R. WILEY
and **RAYMOND G. GOODWIN**

Senior Party,
(Patent No. 5,763,223).

Patent Interference No. 105,077

DECLARATION OF STEVEN M. RUBEN

Wiley EXHIBIT 1032
Ruben v. Wiley et al
Interference 105,077

Paper No. _____

Filed on Behalf of Party Ruben:

By: Samuel B. Abrams, Esq.
Margaret B. Brivanlou, Esq.
JONES DAY
222 East 41st Street
New York, New York 10017
Tel: (212) 326-3939
Fax: (212) 755-7306

UNITED STATES PATENT AND TRADEMARK OFFICE

BEFORE THE BOARD OF PATENT APPEALS
AND INTERFERENCES
(Administrative Patent Judge Sally Gardner Lane)

STEVEN M. RUBEN

Junior Party,
(Application No. 08/816,981),

v.

STEVEN R. WILEY
and RAYMOND G. GOODWIN

Senior Party,
(Patent No. 5,763,223).

Patent Interference No. 105,077

DECLARATION OF STEVEN M. RUBEN

Ruben EXHIBIT 2102
Ruben v. Wiley et al.
Interference No. 105,077
RX 2102

DECLARATION OF STEVEN M. RUBEN

I, STEVEN M. RUBEN, declare and state as follows:

1. I am the same Steven M. Ruben named as the inventor for involved United States patent application 08/816,981. I joined Human Genome Sciences, Inc. (HGS) in 1992 in the position of Scientist, a position I held until 1993. Then, I served as Associate Director of the Molecular Biology Department of HGS from 1993 to 1996, and as Director of the Molecular Biology Department from 1996 to 1998. In 1999, I became Vice President, Research, and eventually became Vice President of Preclinical Discovery, the position that I held when I left HGS in March 2003. I am currently Vice President of Protein Therapeutics at Celera.

2. As Associate Director of the Molecular Biology Department of HGS in the 1993 to 1996 time frame, I supervised and directed the development of a novel Fas Ligand homolog that came to be known as AIM-I (Apoptosis Inducing Molecule-I), an HGS high priority therapeutic protein candidate. During this time, I was responsible for seven Ph.D. scientists and support staff who were focussing on therapeutic protein identification and biological characterization of candidate genes, including AIM-I.

3. AIM-I is referred to by various synonyms in this showing and the supporting documents. In the Wiley '223 patent, AIM-I is referred to as TRAIL, for *TNF related apoptosis inducing ligand*. As explained below, the HGS clone encoding AIM-I is termed HTPAN08. Other identifiers for sequences encoding AIM-I include HTPAN08SO4, 413412 (HGS code) and ATG 343 (code of HGS's collaborators at SmithKline Beecham (see ¶ 32 below)). The AIM-I protein itself is alternatively referred to as TL2, TL-2, TNFL1, Apo2 ligand, APO-2L, and as a homolog of Fas ligand from rat ("rat Fas ligand homolog" or "Fas Ligand" or "FasLig").

4. One of the scientific staff members whom I supervised was Ann Ferrie (formerly known as Ann M. Kim). From 1993 through March 14, 1996, Ms. Ferrie was the primary

individual in my laboratory responsible for carrying out, under my supervision, the benchwork experiments to develop AIM-I as a therapeutic candidate. The AIM-I project was continuously a priority project for Ms. Ferrie throughout this time period. Ms. Ferrie and I would discuss results of her work, including her AIM-I work, on a regular basis, generally two to three times per week, and together we would review the data in her notebook regularly, at which time I would direct the course of the experiments she was to carry out. I would also periodically independently review Ms. Ferrie's laboratory notebooks. I have recently reviewed nine of Ms. Ferrie's Notebooks (HGS Notebook Numbers 82, 127, 168, 202, 236, 270, 345, 405, and 489, also labeled by Ms. Ferrie as Ann Kim #3, #5, #6, #7, #8, #9, #10, #11, and #12; RE87 - RE95 respectively), as well as a loose leaf three ring binder that she maintained, containing sequencing orders and analyses such as BLAST analyses and sequence alignments that Ms. Ferrie performed under my direction specifically for AIM-I (HTPAN08 RE96). As an advanced Research Associate, Ms. Ferrie could follow through on her discussions with me to successfully complete ongoing projects. At the beginning of the AIM-I project, in the 1993 to 1994 time frame, our meetings occurred nearly every day and I would directly instruct her in such tasks as performing BLAST analyses and sequence alignments. As Ms. Ferrie became more experienced, I continued to supervise and direct her work, but she became more independent in carrying out her everyday bench experiments. Ms. Ferrie worked on developing reagents and characterizing AIM-I so the biological activity of the protein could be pursued further in HGS's interdepartmental program for this therapeutic candidate.

5. Each individual bench researcher at HGS, including Ms. Ferrie, maintained a laboratory notebook record of their daily experimental activities. In addition, HGS maintained a separate computerized database known during the 1994-1996 time frame as "IRIS". The IRIS

database summarized company projects on a Project Worksheet form that was an integral part of the technical information record-keeping process at HGS. The content of a Project Worksheet form entered and maintained in the IRIS database was updated by the responsible HGS staff scientists as he or she deemed necessary. The entire content of the electronic database during the time since at least the inception of the AIM-I project was periodically recorded on tape and archived (RE56).

6. On February 2, 1994, I created an electronic project for HTPAN08 (RE97) subsequently revising it on April 14, 1995 (RE99). Specifically, the entry under "POTENTIAL COMMERCIAL VALUE" on the Project Worksheet created on February 2, 1994 (RE97) indicates that clone HTPAN08 encodes "... a potential cytokine with some homology to TNF alpha. TNF alpha has cytotoxic properties against several tumor lines." (RE97 at page 1). In addition, Ms. Ferrie created an electronic project for HTPAN08 on February 8, 1994 (RE98). The BLAST results of the HTPAN08-encoded protein shown in that project worksheet indicate a high degree of homology with rat FasL, TNF α , and lymphotoxin beta, members of the TNF ligand family (RE98).

7. The BLAST search results recorded in the HGS electronic database in February, 1994, clearly indicated that AIM-I had the greatest similarity to Fas ligand, a TNF ligand family member known to induce apoptosis. Accordingly, I expected that AIM-I would also have apoptosis inducing activity. The BLAST analysis indicated that AIM-I was also similar to other TNF ligand family members. Indeed, after rat Fas ligand, the next nearest "hits" in the BLAST search results were all to various forms of TNF α , another TNF ligand family member that was known to induce apoptosis. (RE98).

8. The degree of sequence similarity at key amino acid residues in the carboxy terminal extracellular region of the AIM-I protein with Fas Ligand and TNF α indicated to me in February 1994 that AIM-I would trigger apoptosis. Apoptosis, or programmed cell death, is a specific cellular self-termination protocol which is distinct from necrotic cell death and is characterized by DNA fragmentation or "laddering" and other hallmarks. This protocol is triggered by a subset of ligands within the TNF ligand family. Prototypic examples of such ligands known to induce apoptosis are Fas ligand, TNF α , and LT α . Abundant evidence existed at least as early as 1994 to inform scientists of the well-defined nature of the TNF ligand family (see, e.g., Smith et al., 1994, Cell 76:959-962 (RE03). One of the reasons the TNF ligand family is so well established is because TNF α and LT α (a.k.a. lymphotoxin or TNF β) were among the very first cytokines to be molecularly cloned and sequenced in 1984 and, by 1994, it was concluded that "[t]he contingent ability to induce death is rather unique to [the TNF ligand] family and is well established for TNF α , LT α , and FasL" (Smith (RE03) at page 962, column 1).

9. Additional evidence existed at least as early as 1994 demonstrating that the TNF ligand family contained members, such as Fas Ligand and TNF α , capable of triggering apoptosis (see, e.g., Sachs and Lotem, 1993, Blood 82:15-21 RE107 ; Suda et al., 1993, Cell 75:1169-1178 RE108 ; Cosman, 1994, Stem Cells 12:440-455 RE109 ; Nagata, 1994, Phil. Trans. R. Soc. Lond., Series B: Biol. Sci. (England) 345:281-287 RE110 ; Nagata, 1994, Adv. Immunol. 57:129-144 RE111 ; Schulze-Osthoff, 1994, Trends Cell Biol. 4:421-426 RE112 Singer et al., 1994, Curr. Opin. Immunol. (England) 6:913-920 RE113 ; Nagata, 1994, Semin. Immunol. 6:3-8 RE114 ; and Nagata et al., 1995, Science 267:1449-1456 RE115

The foregoing publications reflect my general knowledge in early 1995 regarding the ability of TNF ligand family members to induce apoptosis.

10. Moreover, considerable insight had been achieved by the time I identified AIM-I as a member of the TNF family into the specific functioning of certain ligand-receptor pairs within the TNF ligand and TNF receptor families, as evidenced by Watanabe-Fukunaga, 1992, *Nature* 356:314-317 RE116 Cohen et al., 1992, *Immunol. Today* 13:427-428 RE117; Crispe, 1994, *Immunity* 1:347-349 RE118 ; Lynch et al., 1994, *Immunity* 1:131-136 RE119 Takahashi et al., 1994, *Cell* 76:969-976 RE120; and Nagata et al., 1995, *Immunol. Today (England)* 16:39-43 RE121. The foregoing publications reflect my general knowledge in early 1995 regarding the associations between TNF ligand and TNF receptor family members.

11. From numerous experiments performed worldwide by a large number of laboratories in recent years, AIM-I has become quite well established as having apoptosis-inducing activity. Indeed, AIM-I and derivatives and fragments of AIM-I are considered leading candidates for therapeutic use in a number of proliferative disease settings. Eight review articles regarding AIM-I provide evidence of the foregoing and discuss the background of AIM-I (Nguyen et al., 2000, *Forum (Genova)* 10:243-52 RE106 ; Schneider et al., 2000, *Pharm. Acta Helv.* 74:281-6 RE122; Walczak et al., 2000, *Exp. Cell Res.* 256:58-66 RE123; Roth et al., 1999, *Cell. Mol. Life Sci.* 56:481-506 RE124; Marsters et al., 1999, *Recent Prog. Horm. Res.* 54:225-34 RE125; Bonavida et al., 1999, *Int. J. Oncol.* 15:793-802 RE126; Griffith et al., 1998, *Curr. Opin. Immunol.* 10:559-63 RE127; and Golstein, 1997, *Curr. Biol.* 7:R750-3 RE128.

SEQUENCE AND CHARACTERIZATION OF HTPAN08

12. On August 8, 1994, Ms. Ferrie printed out the nucleotide sequence and corresponding amino acid sequence of AIM-I (RE96 at pages 73-78). These sequences correspond to the AIM-I sequences disclosed in Figure 1 of Provisional Application No. 60/013,405, filed March 14, 1996 naming me as the inventor. (RE52, Figure 1).

13. On August 9, 1994, under my instruction, Ms. Ferrie performed a BLAST analysis of the amino acid sequence of AIM-I, which revealed high degrees of similarity between AIM-I and several species of TNF alpha and Fas ligand proteins (RE96 at pages 71-72 and 81-85).

14. On August 10, 1994, under my direction, Ms. Ferrie aligned the AIM-I protein amino acid sequence with several other members of the TNF ligand family to highlight the regions of homology among the proteins, including TNF alpha, TNF beta, Fas ligand, and HUVE091 (TNF gamma), a TNF ligand family member that Dr. Guo-Liang Yu, then a scientist at HGS, was studying (RE96 at pages 79-80 and 90-93). I discussed the August 9, 1994 BLAST result and the August 10, 1994 alignment with Ms. Ferrie within a week of August 10, 1994, and I communicated to her that it confirmed for me that the AIM-I protein encoded by HTPAN08SO4 was a full-length member of the TNF ligand family with a high degree of homology to TNF α and FasL and, like those two proteins, would be useful in inducing apoptosis in certain cells. I indicated this use for AIM-I protein in the project report created and modified on February 2, 1994 (RE97 at page 1) and in the project report created on February 2, 1994 and modified on April 14, 1995 (RE99 at page 1).

HGS PROTOCOL FOR CLONES OF HIGH INTEREST

15. Once I recognized the high degree of homology of AIM-I to TNF α and FasL, I had the idea of developing AIM-I based therapeutics, including anti-AIM-I antibodies, for example, for treatment of autoimmune diseases, or the AIM-I protein itself, for example, for treatment of cancer. I recall discussing these ideas with my colleagues, including Reiner Gentz, and also with Ms. Ferrie around the time that we identified the homology between AIM-I and TNF ligand family members mentioned above. Based on these ideas, a decision was made at HGS to pursue the development of AIM-I therapeutics as a matter of high priority in HGS's interdepartmental program. Designating AIM-I a high priority project meant that HGS committed resources to my work on AIM-I to the exclusion of hundreds of other potential therapeutic proteins also being evaluated during this time period. HGS's program for high priority projects involved a variety of discovery platforms in place at HGS to obtain as much information about AIM-I in the quickest manner possible to guide the development of AIM-I related therapeutics. Several of the discovery platforms applied to AIM-I, such as the fluorescence *in situ* hybridization to detect chromosomal location of the AIM-I gene and the indirect immunofluorescence studies of AIM-I protein, as discussed in paragraphs 21 and 30 below, were utilized virtually exclusively in development of therapeutics from molecules of high interest.

16. The initial step in developing AIM-I therapeutics was to obtain a full length clone of AIM-I. We obtained and sequenced a full length clone of AIM-I no later than August 8, 1994 (RE96 at 73-78), therefore, I must have had my ideas regarding the development of AIM-I therapeutics, and HGS must have made the decision to make the development of AIM-I therapeutics a "high interest" project, prior to this August 8, 1994 date.

17. One discovery platform used for developing AIM-I therapeutics was the protein expression platform. In addition to the bacterial expression of AIM-I performed by Ms. Ferrie (see paragraph 25), the Protein Expression Group at HGS, under the supervision of Dr. Reiner Gentz, spent extensive efforts to develop an insect expression system for AIM-I as part of a TNF ligand and TNF receptor family expression program, as described in paragraph 26 below. Additionally, expression of AIM-I in the rabbit reticulocyte lysate system was performed (paragraphs 27 and 28 below) to ensure that the proper signals for protein translation were present in our AIM-I clones. The assessment of a variety of expression constructs in a variety of expression systems allowed us to identify the most suitable scheme for expressing large amounts of AIM-I protein in the fastest and most economic manner possible for the development of AIM-I related therapeutics.

18. In addition to the protein expression platform, bacterially-produced AIM-I protein was sent to the Pocono Rabbit Farm and Laboratories for the generation of anti-AIM-I antibodies (see paragraph 31 below) in June of 1995. In that time period, antibody production was part of a protocol in place at HGS for characterizing and developing molecules of high therapeutic interest.

19. Another discovery platform in place at HGS for high interest genes was expression analysis through Northern blotting (see paragraph 29 below). Northern blotting is used to assess the tissue specificity and cell specificity of expression of the AIM-I gene. This information, for example whether or not AIM-I is expressed in cancer cells and immune system cells, is important for developing animal models and test protocols when assessing AIM-I therapeutics.

20. Yet another discovery platform in place at HGS for the development of therapeutically relevant molecules was indirect immunofluorescence, which involved expressing epitope-tagged proteins in mammalian cells to evaluate whether the proteins were properly processed and localized in the appropriate subcellular compartment. Because this platform demanded a considerable amount of HGS resources, its use was limited to molecules that were deemed to be of a very high priority for therapeutic development. AIM-I was considered to be such a molecule, and thus indirect immunofluorescence of AIM-I protein was performed by Ms. Ferrie (see paragraph 30 below).

21. In addition to the development platforms described in paragraphs 15 through 20 above, the chromosomal location of AIM-I was determined by the HGS Exploratory Research group, headed by Ken Carter (see paragraphs 34 to 37 below) as part of the AIM-I therapeutic development program. This mapping experiment was carried out to correlate the physical position of AIM-I on the chromosome with known genetic map data and to further elucidate the biological role of AIM-I and its value as therapeutic agent. In particular, such mapping data provides useful information as a genetic marker in mapping the human genome, in localizing chromosome regions associated with diseases such as cancer, and in potentially correlating AIM-I and diseases that may map to the same chromosomal region. They also confirm that the cDNA is encoded by a specific gene in the human genome, and, therefore, encodes a naturally occurring protein. The human AIM-I gene was determined to specifically map to chromosome 3q25-27. Because of the labor-intensive nature of chromosome mapping, this type of analysis was reserved solely for proteins of the highest therapeutic interest at HGS.

22. The efforts undertaken in the development of AIM-I therapeutics, as summarized in paragraphs 15 through 21 above, took place in 1993 through 1996. These efforts reflect an

immense commitment on HGS's part at a time when HGS, founded in 1992, was no more than a young start-up company.

PRODUCTION AND CHARACTERIZATION OF AIM-I PROTEIN

23. Once I had determined that a full-length cDNA encoding AIM-I had been cloned, I directed a great deal of effort from early 1994 up to and beyond March 14, 1996 to produce the full-length AIM-I protein in a variety of gene expression systems, as detailed below. The activities carried out in my laboratory in this endeavor from early 1994 up to and beyond March 14, 1996 are recorded in part in Ms. Ferrie's laboratory notebooks (HGS Notebook Numbers 82, 127, 168, 202, 236, 270, 345, 405, and 489, labeled by Ms. Ferrie as Ann Kim #3, #5, #6, #7, #8, #9, #10, #11, and #12; RE87 -RE95, respectively). Recombinant production of AIM-I protein is one of the first steps one must take in order to prepare the protein to generate what I refer to herein as "AIM-I therapeutics," such as anti-AIM-I antibodies for therapeutic use, for example, for treatment of autoimmune diseases, or therapeutics comprising the protein itself, for example for treatment of cancer. Also, protein production *in vitro* and *in vivo* is generally helpful for determining the various characteristics of a new protein, such as its membrane topology, glycosylation pattern, and posttranslational processing, if any, and the correct (*i.e.* natural) protein translation initiation site. In addition, I directed the production of recombinant AIM-I as a reagent for analyzing its biological activity, and for raising anti-AIM-I antibodies for analyzing the expression patterns and function of the protein and for developing the antibodies as therapeutic reagents.

24. In January 1995, I directed the successful bacterial expression and subsequent purification of AIM-I protein. Expression constructs encoding two different forms of AIM-I were generated in order to develop an expression system that yielded high levels of AIM-I

protein to facilitate development of AIM-I therapeutics: (a) construct HTPAN08SO4 185bp was used to generate a protein with translation beginning at the 45th residue of the AIM-I open reading frame, *i.e.* methionine 45 ("Met-45"); and (b) construct HTPAN08SO4 51 bp was used to generate a protein with translation beginning at the first residue of the open reading frame, *i.e.* methionine 1 ("Met-1"). These two forms of AIM-I were cloned into three different vectors, pD10, pQE60 and pA2. pD10 and pQE60 are bacterial expression vectors whereas pA2 is a baculovirus vector for expression in Sf9 insect cells.

25. Bacterial expression of AIM-I provided an abundant source of AIM-I antigen used for the production of polyclonal antibodies. Moreover, AIM-I expressed in bacteria provided a potential source of protein for use in assays designed to demonstrate apoptotic activity.

26. Insect cell expression provides for the production of protein having a eukaryotic glycosylation pattern. The Sf9 system is one of three major, routine expression systems that have been used at HGS to determine the optimal expression system. Once Ms. Ferrie made the AIM-I Sf9 expression constructs, the constructs were provided to the HGS Protein Expression Group, headed by Dr. Reiner Gentz, for expression of AIM-I in Sf9 insect cells. I communicated with Dr. Gentz regarding the progress of this project on a regular basis, and Dr. Gentz kept me abreast of the significant efforts in 1995 to express AIM-I in the insect cell system. In addition to expression of AIM-I protein, the Protein Expression Group was evaluating expression systems for the TNF ligand family members TNF gamma (also referred to as VEGI or HUVEO91) and TNF delta. Because of the high degree of similarity among TNF ligand family members, we anticipated that information regarding suitable expression systems for TNF ligands such as TNF gamma and TNF delta would also be useful to determine the most

suitable approach to express AIM-I protein for the development of AIM-I therapeutics. Among the members of the Protein Expression Group working on elucidating suitable expression conditions of AIM-I and other TNF ligand family members in 1995 and 1996 under the ultimate supervision of Dr. Gentz were Dr. Timothy Coleman, Dr. Guo-Liang Yu, Solange Gentz (then known as Solange Lima), Lily Xing, and Markus Buergin.

27. Rabbit reticulocyte lysates are commonly used for *in vitro* translation of messenger RNA transcripts. Many commercial kits are available for the performance of this assay, wherein the user provides the mRNA encoding the protein of interest. This experimental system can be used to answer a number of important questions about a protein and its encoding nucleic acids. For example, it is convenient for determining whether a correct cDNA construct has been assembled and isolated. If complementary RNA (cRNA) transcribed from a cDNA construct under study can be translated *in vitro* to produce a protein in reticulocyte lysates, then the user is assured that the construction encodes viable translation initiation and termination signals, *i.e.*, it confirms that the gene is expressible.

28. *In vitro* expression of AIM-I protein was achieved by August 25, 1994 (RE90 pages 33-34). The significance of AIM-I expression was at least fourfold: (a) confirmation of the correctness of a properly transcribable and translatable reading frame; (b) confirmation of the correctness of the predicted molecular weight; (c) production of a reagent suitable for use in antibody production; and (d) production of a reagent for demonstration of therapeutic use in biological activity assays (*e.g.* killing cancer or immune cells).

29. Northern blots, or RNA blots, provide an indication of the tissue specificity and cell specificity of expression of AIM-I. The mRNA expression pattern is useful in predicting, confirming, or even determining the function of a new gene, such as AIM-I. In particular,

determining the expression pattern of AIM-I would be useful in identifying the likely target receptor and target cell type for AIM-I. Northern analyses were carried out by Ms. Ferrie under my direction in December 1995 for the purpose of determining the expression pattern and tissue specificity of AIM-I.

30. Indirect immunofluorescence analysis of the AIM-I protein was undertaken as part of my overall effort to obtain a detailed understanding of the biological properties of AIM-I as they exist in a living mammalian cell, and to ensure proper processing of the AIM-I protein to produce a biologically active protein. Generally, immunocytochemistry can be used to reveal the subcellular localization of a protein. Moreover, a protein under study can be genetically engineered to display antigen tags at various locations along the linear sequence of the protein, such as at the N-terminus and the C-terminus. The tagged protein can then be subjected to immunocytochemical analysis to reveal the subcellular localization of specific antigen-tagged portions of the protein. Such an approach can reveal important information about protein processing, topology, and orientation within cellular membranes. The immunofluorescence experiments that Ms. Ferrie carried out under my direction in 1995 were designed to determine the sub-cellular location of the AIM-I protein.

31. As noted above, bacterially produced recombinant AIM-I was used as a source for raising anti-AIM-I antibodies. These anti-AIM-I antibodies were raised by Pocono Rabbit Farm and Laboratories (PRF&L) in rabbits using recombinant AIM-I protein that Ms. Ferrie produced and sent to PRF&L under my direction in June of 1995; and the antibodies produced were sent to my laboratory by PRF&L throughout the production process until the final exsanguination of the rabbits and receipt of the final antisera at HGS in January 1996. These antibodies, samples of which were used by Ms. Ferrie under my direction in Western analyses between August 30, 1995

and March 14, 1996, were raised for the purpose of studying the expression patterns and activity of the AIM-I protein, as well as confirming its production through recombinant constructs.

JOINT PROGRAM WITH SMITHKLINE BEECHAM

32. Because of the great interest within HGS in the TNF ligand family, including in particular AIM-I, a joint program was established between HGS and SmithKline Beecham ("SB") (the "HGS/SB Joint Program") to commit greater resources toward developing these ligands and their receptors as potential therapeutic agents. Dr. Reiner L. Gentz, who at the time was Director of Protein Expression and Purification at HGS, managed HGS's involvement in this HGS/SB Joint Program. Thus, in addition to the work being conducted on AIM-I under my direction in my laboratory and in other HGS departments as described herein, the HGS/SB Joint Program included activities by Dr. Jian Ni, Dr. Guo-Liang Yu, Dr. Yu's assistant Lily Xing, each of HGS; and Alem Truneh and several scientists at SB. From time to time during the HGS/SB Joint Program, including during the 1995 to 1996 time period, members of the HGS/SB Joint Program held official meetings to discuss their progress in this program. One such meeting took place on October 18, 1995, and although I did not attend that meeting, I reviewed the meeting abstracts and minutes. RE71 shortly after the meeting. In addition to obtaining information from formal meetings of the HGS/SB Joint Program, I communicated directly with HGS and SB personnel about the progress of analysis of the TNF Ligand and Receptor family members, including AIM-I.

7/23/01
7/23/01
7/23/01
7/23/01

33. To better understand the role and mechanism of AIM-I apoptotic activity, it was important to identify such TNF receptor family members to ultimately determine which receptors did and did not bind AIM-I. Also key to this analysis of AIM-I function was to compare and contrast the expression patterns of the various members of both the TNF ligand (e.g. TNF

gamma, delta, and epsilon) and TNF receptor (e.g. TR1, TR2, and TR3) families, and thereby identify the likely target receptors and target cell lines for AIM-I. Therefore, work carried out by HGS and SB scientists from early 1995 through March 1996 on various TNF ligand and receptor family members, such as TNF gamma, delta, and epsilon, and TR1, TR2, and TR3 all contributed to further elucidating the biological function of AIM-I.

CHROMOSOMAL MAPPING

34. In late 1995, I undertook to map the chromosomal locus of the AIM-I gene. This mapping experiment was carried out to correlate the physical position of AIM-I on the chromosome with known genetic map data and to further elucidate the biological role of AIM-I and its value as therapeutic or diagnostic agent. In particular, such mapping data provides useful information as a genetic marker in mapping the human genome, in localizing chromosome regions associated with diseases such as cancer, and in potentially correlating AIM-I and diseases that may map to the same chromosomal region. They also confirm that the cDNA is encoded by a specific gene in the human genome, and, therefore, encodes a naturally occurring protein. The human AIM-I gene was determined to specifically map to chromosome 3q25-27.

35. On November 29, 1995, I made an internal HGS request for chromosomal mapping of the AIM-I gene, as indicated on the standard HGS order form DNA Probe for Chromosomal Mapping Request #279 order form, dated November 29, 1995 RE103. I made this request for the intended purpose of mapping the AIM-I gene and I expected the clone to map to a specific position in the human genome.

36. On November 30, 1995, an AIM-I nucleic acid probe was labeled for the chromosomal mapping procedure by Meena Augustus, who was a chromosomal mapping

technician in the HGS Exploratory Research department supervised by Ken Carter at that time (Augustus notebook 346 RE104 at page 97).

37. On December 5, 1995, AIM-I was determined to map to chromosome 3q25-27; and on December 6, 1995, the mapping information was entered into IRIS RE104 at page 101). The result of the mapping experiment was communicated to me by either Ken Carter or one of his assistants within two to three days of December 5, 1995.

PATENT RELATED ACTIVITY

38. I personally assisted in the preparation of a provisional patent application directed to AIM-I. On or about January 30, 1996, I completed and forwarded to the HGS Legal Department a patent questionnaire to be used in preparing the provisional patent application

RE105

39. On or about February 12, 1996, I delivered samples of AIM-I cDNA (DNA Plasmid 413412) encoding AIM-I that Ms. Ferrie had aliquoted out to the HGS Legal Department for depositing with the American Type Culture Collection in connection with filing a provisional patent application directed to AIM-I (RE95 page 20).

40. On March 8, 1996, I discussed the preparation of the provisional patent application directed to AIM-I by telephone with Charles Herron, outside patent counsel at Carella, Byrne, Bain, Gilfillan, Cecchi, Stewart & Olstein ("Carella") (RE50).

41. On March 14, 1996, I directly corresponded by telefacsimile with Mr. Herron of Carella regarding the final preparation of the aforementioned provisional application, including providing Mr. Herron with data and materials to be included in the application (RE51).

42. I hereby declare that all statements made herein of my own knowledge are true and that all statements made on information and belief are believed to be true; and further that

these statements were made with the knowledge that willful false statements and the like so made are punishable by fine or imprisonment, or both, under § 1001 of Title 18 of the United States Code, and that such willful false statements may jeopardize the validity of the application captioned above or any patent issuing thereupon.

Date: 6/24/09

Steven M. Ruben

**This Page is Inserted by IFW Indexing and Scanning
Operations and is not part of the Official Record**

BEST AVAILABLE IMAGES

Defective images within this document are accurate representations of the original documents submitted by the applicant.

Defects in the images include but are not limited to the items checked:

- BLACK BORDERS**
- IMAGE CUT OFF AT TOP, BOTTOM OR SIDES**
- FADED TEXT OR DRAWING**
- BLURRED OR ILLEGIBLE TEXT OR DRAWING**
- SKEWED/SLANTED IMAGES**
- COLOR OR BLACK AND WHITE PHOTOGRAPHS**
- GRAY SCALE DOCUMENTS**
- LINES OR MARKS ON ORIGINAL DOCUMENT**
- REFERENCE(S) OR EXHIBIT(S) SUBMITTED ARE POOR QUALITY**
- OTHER:** _____

IMAGES ARE BEST AVAILABLE COPY.

As rescanning these documents will not correct the image problems checked, please do not report these problems to the IFW Image Problem Mailbox.